PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Novartis is clinical pharmacology regonol (pyridostigmine bromide injection, usp) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. First approved in 2017.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY REGONOL (pyridostigmine bromide injection, USP) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. Currently available data indicate that pyridostigmine may have a…
Worked on PYRIDOSTIGMINE BROMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.